PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease.
CHAARTED
Oncology: GU
PET
PET/CT
PSMA
mHSPC
metastasis-directed treatment
prostate cancer
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
14 May 2021
14 May 2021
Historique:
received:
11
02
2021
accepted:
19
03
2021
entrez:
15
5
2021
pubmed:
16
5
2021
medline:
16
5
2021
Statut:
aheadofprint
Résumé
Conventional imaging low-(LVD) versus high-volume disease (HVD) are associated with survival in metastatic hormone-sensitive prostate cancer (mHSPC) according to CHAARTED and STAMPEDE trials. We propose a compatible quantitative PSMA-PET framework for disease volume assessment in mHSPC.
Identifiants
pubmed: 33990403
pii: jnumed.121.262120
doi: 10.2967/jnumed.121.262120
pmc: PMC8612183
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Références
Radiology. 1983 Sep;148(3):839-43
pubmed: 6878708
Lancet. 2018 Dec 1;392(10162):2353-2366
pubmed: 30355464
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
Clin Cancer Res. 2019 Dec 15;25(24):7448-7454
pubmed: 31511295
JAMA Oncol. 2019 Jun 1;5(6):856-863
pubmed: 30920593
J Clin Oncol. 2018 Feb 10;36(5):446-453
pubmed: 29240541
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
JAMA Oncol. 2020 May 1;6(5):650-659
pubmed: 32215577
J Nucl Med. 2018 Mar;59(3):469-478
pubmed: 29123012
Lancet. 2019 May 18;393(10185):2051-2058
pubmed: 30982687
J Nucl Med. 2019 Sep;60(9):1277-1283
pubmed: 30850484